MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.29 -3.73

Buy Sell

Overview

Share price change

24h

Current

Min

1.25

Max

1.35

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+52.67% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-36M 138M
Previous open	5.02
Previous close	1.29

News Sentiment

By Acuity

50%

156 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 kwi 2026, 23:36 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 kwi 2026, 23:24 UTC

Hot Stocks

Stocks to Watch: Gloo, Broadcom, GitLab

14 kwi 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 kwi 2026, 21:32 UTC

Major Market Movers

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 kwi 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 kwi 2026, 22:54 UTC

Earnings

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 kwi 2026, 22:54 UTC

Earnings

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 kwi 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 kwi 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 kwi 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 kwi 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 kwi 2026, 22:13 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 kwi 2026, 22:12 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 kwi 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

14 kwi 2026, 20:33 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 20:32 UTC

Hot Stocks

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 kwi 2026, 19:59 UTC

Acquisitions, Mergers, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 kwi 2026, 19:38 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 kwi 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 kwi 2026, 19:21 UTC

Market Talk

Major News Events

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 kwi 2026, 19:09 UTC

Acquisitions, Mergers, Takeovers

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 kwi 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 kwi 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

52.67% upside

12 Months Forecast

Average 2 USD 52.67%

High 2 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

156 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.